Covista Inc. (CVSA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Covista Inc. stock $153, price $110, upside +38.5%, quality 77 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $19.74 – $154.45 · fair‑value band $110.91 – $194.67 · the $110.32 price screens below the $152.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Covista in your weekly email
Every Wednesday you see whether Covista is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary.
Show moreShow less
The company offers degree and non-degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.
The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc. was incorporated in 1987 and is headquartered in Chicago, Illinois.
Stock analysis
Covista Inc. (CVSA) currently trades at $110.32, while our model-based Fair Value estimate is $152.79, implying the stock looks roughly 28% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $181.33 per share, and 14 of the 22 models we run sit above the $110.32 price.
Bear case: the Earnings-Based group reads lowest at $72.33, and 8 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $110.91 (bear) to $194.67 (bull), the price of $110.32 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Covista Inc. reported revenue of $2.0B in FY2026 versus $1.4B in FY2022, a compound +9.0%/yr. Reported net income was $252M in FY2026.
Key figures
Market cap $3.7B Mid · P/E ratio 13.9 · P/S ratio 1.87 · EPS (TTM) $7.92 · Net margin 12.8% · Return on equity 19.3% · Return on assets (EBIT) 9.3% (5-year average) · Operating margin 19.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 27% fair-value upside, at 38%, CVSA screens cheaper than that median.
Fair Value models
Bear$110.91Fair Value $152.79Bull$194.67
Price $110.32 · Upside +38.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then ($2.84 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 4 officers or directors sold shares worth $5.5M and none bought.
SaleStephen W. BeardChairman & CEO5× since May 8, 2026: 38,307 shares, avg. $131.12$5.0MOct 9, 202610b5-1 plan
SaleManjunath GangadharanVP, Chief Accounting Officer1,802 shares at $137.18$247,198Aug 27, 202610b5-1 plan
SaleDouglas G. BeckSVP, GC, Corp. Sec & ISS3× since May 8, 2026: 19,230 shares, avg. $131.30$2.5MAug 7, 202610b5-1 plan
SaleRobert J. PhelanChief Financial Officer3× since May 8, 2026: 17,500 shares, avg. $130.12$2.3MAug 7, 202610b5-1 plan
SaleKaren Sue CoxPresident, Chamberlain Univ.2,000 shares at $124.50$249,000May 8, 202610b5-1 plan
BuyMichael W MalafronteDirector2× since Mar 3, 2026: 37,236 shares, avg. $100.79$3.8MMar 11, 2026
Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Start year 2021 (pandemic). Over 10 years: +0.6% a year
Revenue growth 37 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+44.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+44.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.22.6% vs 13.6%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 20%
2026 sits 113% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −6.4% a year for the price and +3.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Tech-enabled programs that let working adults enter healthcare roles at scale across five institutions form the main strength, yet thin public data leaves no clear durable moat and execution risks remain.
Main risk: Execution stretch in the regulated healthcare education field could limit the company's ability to scale programs and meet compliance requirements across its institutions.
Covista builds flexible, tech-enabled programs that let working adults enter healthcare roles at scale across its five institutions. It has moved from Growth with Purpose to Purpose at Scale, adding employer ties and AI tools to personalize clinical training. Will these steps widen its lead in filling workforce gaps, or will they stretch execution in a regulated field?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Education & Training Services · 108 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+38.5% · Above median
Profitability
Return on equity (12 months)19.3% · Top 25%
Return on assets8.4% · Top 25%
Net margin (12 months)12.8% · Above median
Operating margin (12 months)19.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.7% · Above median
Balance sheet
Debt / equity0.46× · Above median
Valuation Multiplesvs Education & Training Services median · lower = cheaper
P/E (12 months)13.9× · Cheaper than median
P/B2.58× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)1.87× · Pricier than median
Price / free cash flow (fiscal year)9.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Covista Inc. Fair Value". https://www.fairvalue-calculator.com/stock/CVSA
Frequently asked questions
Is Covista Inc. (CVSA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $152.79 versus a price of $110.32, about +38% upside (undervalued).
What is the fair value of CVSA?
Our model-based fair value for Covista Inc. is $152.79 (as of Nov 6, 2026), built from audited fundamentals. The current price: $110.32.
What is the quality score of CVSA?
Covista Inc. has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Covista Inc. (CVSA)?
Our model-based price target is the fair value of $152.79 (as of Nov 6, 2026) from 22 valuation models. Cautious scenario $110.91, optimistic scenario $194.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Covista Inc. stock forecast for 2026?
Our models put fair value at $152.79, about +38% upside versus a price of $110.32 (undervalued). Cautious scenario $110.91, optimistic scenario $194.67. The calculation is refreshed regularly with new filings.
What is the revenue of Covista Inc. (CVSA)?
Covista Inc. reported trailing-twelve-month revenue of about $2.0B (latest available figure, as of Nov 6, 2026).
What growth is priced into Covista Inc. (CVSA)?
For today's price to be fair in a discounted-cash-flow model, Covista Inc. would have to grow free cash flow by -4.2 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CVSA use?
Our models discount Covista Inc. at 8.9 %: a base by market capitalisation (mid), damped by beta 0.65, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Covista Inc. that is -4.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Covista Inc. (CVSA) delivered so far?
Over the past 5 years revenue at Covista Inc. grew +16.6 % a year. The price currently implies free-cash-flow growth of -4.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Covista Inc. (CVSA) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into Covista Inc. (-4.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Covista Inc. (CVSA)?
The free-cash-flow yield on the price is 10.24 %: that much free cash flow Covista Inc. produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Covista Inc. (CVSA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Covista Inc. it is $152.79 per share (as of Nov 6, 2026), against a price of $110.32. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Covista Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CVSA trades below its calculated fair value: price $110.32, fair value $152.79, a gap of about +38% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVSA?
No. The price is what the market pays today ($110.32); the fair value is what the company's own numbers justify ($152.79). For Covista Inc. the two are $42.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Covista Inc. worth?
The market values Covista Inc. at about $3.7B (market capitalisation, as of Nov 6, 2026). Per share that is $110.32; our models calculate a fair value of $152.79 per share.
What do the bullish and bearish scenarios say about CVSA?
Our models span a range for Covista Inc.: cautious scenario $110.91, base $152.79, optimistic $194.67 per share (as of Nov 6, 2026, price $110.32). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CVSA?
Covista Inc. trades at a price-to-earnings ratio of 13.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $152.79 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2026), reported earnings: 20.1. Other multiples: PEG 0.9, P/B 2.6, P/S 1.9, EV/EBITDA 8.7.
What is the PEG ratio of CVSA?
The PEG ratio of Covista Inc. is 0.92 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Covista Inc. (CVSA)?
Balance-sheet figures for Covista Inc. (as of Nov 6, 2026): return on equity 19.3%, debt of 0.46 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is CVSA from its 52-week high?
Covista Inc. trades at $110.32, about 22% below its 52-week high of $140.98 and 23% above the low of $89.36 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $152.79 is for.
Which stocks are comparable to Covista Inc.?
From the same area (Consumer Defensive) we also value New Oriental Education & Technology Group, Laureate Education, Inc, Physicswallah Limited, Grand Canyon Education, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Covista Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price $110.32, calculated fair value $152.79 (+38%), Quality Score 77/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CVSA calculated?
We run Covista Inc. through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $152.79 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Covista Inc. currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Covista Inc. (CVSA)?
The closing price on Nov 6, 2026 was $110.32. Our model-based fair value is $152.79, about +38% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Covista Inc. right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price sits below our cautious bear case: the market assumes less than even our pessimistic scenario. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Covista Inc. (CVSA) come from?
Earnings per share at Covista Inc. grew +11.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +7.7 %, EBIT margin +5.7 %, tax rate −1.5 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Covista Inc.
How large is the market capitalisation of Covista Inc. (CVSA)?
The market capitalisation of Covista Inc. is $3.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Covista Inc. (CVSA)?
The price-to-sales ratio of Covista Inc. is 1.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Covista Inc. (CVSA)?
Earnings per share at Covista Inc. are $7.92 (price ÷ EPS = P/E 13.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Covista Inc. (CVSA)?
The net margin of Covista Inc. is 12.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Covista Inc. (CVSA)?
The return on equity (ROE) of Covista Inc. is 19.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Covista Inc. (CVSA)?
On an EBIT basis the return on assets of Covista Inc. is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Covista Inc. (CVSA)?
The operating margin of Covista Inc. is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Covista Inc. (CVSA)?
Revenue at Covista Inc. is growing +10.7% versus a year earlier (3y avg +10.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Covista Inc. (CVSA)?
Earnings per share at Covista Inc. are growing +16.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Covista Inc. (CVSA) carry?
The net debt of Covista Inc. is $499M (fiscal year 2026, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Covista Inc. in the live analysis
One click puts Covista Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026